Joseph J. Sacco, Kevin Joseph Harrington, Andres Cervantes, Maria de Miguel, Guzman Alonso, Sara Valpione, Anna Olsson-Brown, Tze Y. Chan, Pablo Nenclares, Isla Leslie, Praveen Bommareddy, Alireza Kalbasi, Ben Xie, Dishan Liu, Danielle Ulanet, Vineetha Edavana, Gary Vanasse, Francesca Aroldi, Aglaia Skolariki, Mark R. Middleton. "RP2 oncolytic immunotherapy alone and in combination with nivolumab (nivo) in patients with advanced solid tumors: Final safety, efficacy, and biomarker results from the phase 1 first-in-human (FIH) study.." Journal of Clinical Oncology, 2026. doi:10.1200/jco.2026.44.16_suppl.2504